We design peptides with purpose – for globally important therapeutic applications.

About us

Peptilogics is a clinical-stage biotechnology company developing a new platform technology leveraging computational and rational design principles which enables us to rapidly and effectively develop novel peptide therapeutics for unmet patient needs.

Our first set of therapeutic discovery programs spans orthopedics and anti-infectives applications, where we demonstrated best-in-class efficacy and first-in-class clinical safety, and have been awarded FDA QIDP and FDA Orphan designation.


Backed by global life science investors.

Investment firm of Peter Thiel, track record of industry-defining companies.

Led by co-founder of company that became Alnylam ($18B market cap).

Global $600M infectious disease fund, backed by US, UK, Germany, Gates Foundation.


Stay updated on our clinical trials and partnerships.

Contact us and follow us on Twitter and LinkedIn.

© 2020 Peptilogics  I  All Rights Reserved